中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肝纤维化逆转的研究进展

李满彪 李金玉 冯对平

引用本文:
Citation:

肝纤维化逆转的研究进展

DOI: 10.3969/j.issn.1001-5256.2023.01.030
基金项目: 

山西省重点研发计划社会发展项目 (201903D321188)

山西省科学技术厅面上项目 (20210302123258)

利益冲突声明:所有作者均声明不存在利益冲突。
作者贡献声明:李满彪负责拟定写作思路,检索文献,撰写论文;冯对平、李金玉负责指导、修改论文并最终定稿。
详细信息
    通信作者:

    冯对平, fengdp@sxmu.edu.cn (ORCID: 0000-0003-4516-3797)

Research advances in the reversal of liver fibrosis

Research funding: 

Social Development Project of Shanxi Key Research and Development Plan (201903D321188);

Department of Science and Technology of Shanxi Province, General Project (20210302123258)

More Information
  • 摘要: 任何病因引起的慢性肝损伤都会导致肝纤维化,过去认为肝纤维化是一种静态的、不可逆转的病理生理过程。近年来,随着分子生物学的飞速发展,以及对肝脏微观层面的不断深入研究,越来越多的证据表明肝纤维化是一种动态的、可逆的过程。本文回顾了不同方法评价各种病因导致的肝纤维化逆转的报道,总结了肝纤维化的发病机制及其逆转的机制,并回顾了逆转的治疗药物,归纳目前肝纤维化的评估方法,最后认为及时清除或控制潜在病因,肝纤维化会出现不同程度的逆转。

     

  • [1] AYDIN MM, AKÇALI KC. Liver fibrosis[J]. Turk J Gastroenterol, 2018, 29(1): 14-21. DOI: 10.5152/tjg.2018.17330.
    [2] ZOUBEK ME, TRAUTWEIN C, STRNAD P. Reversal of liver fibrosis: From fiction to reality[J]. Best Pract Res Clin Gastroenterol, 2017, 31(2): 129-141. DOI: 10.1016/j.bpg.2017.04.005.
    [3] CHEN S, ZHOU J, WU X, et al. Comparison of fibrosis regression of entecavir alone or combined with pegylated interferon alpha2a in patients with chronic hepatitis B[J]. Hepatol Int, 2021, 15(3): 611-620. DOI: 10.1007/s12072-021-10162-1.
    [4] ZAKAREYA T, ELHELBAWY M, ELZOHRY H, et al. Long-term impact of hepatitis C virus eradication on liver stiffness in egyptian patients[J]. Can J Gastroenterol Hepatol, 2021, 2021: 4961919. DOI: 10.1155/2021/4961919.
    [5] NONO JK, FU K, MPOTJE T, et al. Investigating the antifibrotic effect of the antiparasitic drug Praziquantel in in vitro and in vivo preclinical models[J]. Sci Rep, 2020, 10(1): 10638. DOI: 10.1038/s41598-020-67514-4.
    [6] DIENSTAG JL, GOLDIN RD, HEATHCOTE EJ, et al. Histological outcome during long-term lamivudine therapy[J]. Gastroenterology, 2003, 124(1): 105-117. DOI: 10.1053/gast.2003.50013.
    [7] ABAYLI B, ABAYLI C, GENCDAL G. Histopathological evaluation of long-term tenofovir disoproxil fumarate treatment in patients with hepatitis be antigen-negative chronic hepatitis B[J]. World J Gastrointest Pharmacol Ther, 2021, 12(2): 32-39. DOI: 10.4292/wjgpt.v12.i2.32.
    [8] SUN YM, CHEN SY, YOU H. Regression of liver fibrosis: evidence and challenges[J]. Chin Med J (Engl), 2020, 133(14): 1696-1702. DOI: 10.1097/CM9.0000000000000835.
    [9] ZENG DB, DI L, ZHANG RC, et al. The effect of splenectomy on the reversal of cirrhosis: a prospective study[J]. Gastroenterol Res Pract, 2019, 2019: 5459427. DOI: 10.1155/2019/5459427.
    [10] ZHAO YL. Cirrhosis portal hypertension liver fibrosis before and after TIPS Change analysis of indicators[D]. Xining: Qinghai University, 2019.

    赵艳玲. 肝硬化门脉高压TIPS术前后肝纤维化指标的变化分析[D]. 西宁: 青海大学, 2019.
    [11] PANG N, ZHAO C, LI J, et al. Body mass index changes after transjugular intrahepatic portosystemic shunt in individuals with cirrhosis[J]. Nutrition, 2021, 84: 111095. DOI: 10.1016/j.nut.2020.111095.
    [12] MATSUDA M, SEKI E. Hepatic stellate cell-macrophage crosstalk in liver fibrosis and carcinogenesis[J]. Semin Liver Dis, 2020, 40(3): 307-320. DOI: 10.1055/s-0040-1708876.
    [13] KISSELEVA T, BRENNER D. Molecular and cellular mechanisms of liver fibrosis and its regression[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(3): 151-166. DOI: 10.1038/s41575-020-00372-7.
    [14] XUE Y, QIAN K, SUN Y, et al. Application of TGF-β1, TIMP-1 and TIMP-2 small interfering RNAs can alleviate CCl4-induced hepatic fibrosis in rats by rebalancing Th1/Th2 cytokines[J]. Exp Ther Med, 2021, 22(3): 963. DOI: 10.3892/etm.2021.10395.
    [15] LACHOWSKI D, CORTES E, RICE A, et al. Matrix stiffness modulates the activity of MMP-9 and TIMP-1 in hepatic stellate cells to perpetuate fibrosis[J]. Sci Rep, 2019, 9(1): 7299. DOI: 10.1038/s41598-019-43759-6.
    [16] ZHANG J, LIU Y, CHEN H, et al. MyD88 in hepatic stellate cells enhances liver fibrosis via promoting macrophage M1 polarization[J]. Cell Death Dis, 2022, 13(4): 411. DOI: 10.1038/s41419-022-04802-z.
    [17] European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398. DOI: 10.1016/j.jhep.2017.03.021.
    [18] CAMPANA L, ESSER H, HUCH M, et al. Liver regeneration and inflammation: from fundamental science to clinical applications[J]. Nat Rev Mol Cell Biol, 2021, 22(9): 608-624. DOI: 10.1038/s41580-021-00373-7.
    [19] SHOKRAVI S, BORISOV V, ZAMAN BA, et al. Mesenchymal stromal cells (MSCs) and their exosome in acute liver failure (ALF): a comprehensive review[J]. Stem Cell Res Ther, 2022, 13(1): 192. DOI: 10.1186/s13287-022-02825-z.
    [20] WU W, LI L, YANG J, et al. Therapeutic effect of biejiaxiaozheng pills on carbon tetrachloride-induced hepatic fibrosis in rats through the NF-κB/Nrf2 pathway[J]. Gastroenterol Res Pract, 2021, 2021: 3954244. DOI: 10.1155/2021/3954244.
    [21] KAMM DR, MCCOMMIS KS. Hepatic stellate cells in physiology and pathology[J]. J Physiol, 2022, 600(8): 1825-1837. DOI: 10.1113/JP281061.
    [22] KUMAR V, XIN X, MA J, et al. Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis[J]. Adv Drug Deliv Rev, 2021, 176: 113888. DOI: 10.1016/j.addr.2021.113888.
    [23] JIANG H, LIU J, ZHANG K, et al. Saikosaponin D inhibits the proliferation and promotes the apoptosis of rat hepatic stellate cells by inducing autophagosome formation[J]. Evid Based Complement Alternat Med, 2021, 2021: 5451758. DOI: 10.1155/2021/5451758.
    [24] XIU AY, DING Q, LI Z, et al. Doxazosin attenuates liver fibrosis by inhibiting autophagy in hepatic stellate cells via activation of the PI3K/Akt/mTOR signaling pathway[J]. Drug Des Devel Ther, 2021, 15: 3643-3659. DOI: 10.2147/DDDT.S317701.
    [25] YU HX, YAO Y, BU FT, et al. Blockade of YAP alleviates hepatic fibrosis through accelerating apoptosis and reversion of activated hepatic stellate cells[J]. Mol Immunol, 2019, 107: 29-40. DOI: 10.1016/j.molimm.2019.01.004.
    [26] GUO Q, CHEN M, CHEN Q, et al. Silencing p53 inhibits interleukin 10-induced activated hepatic stellate cell senescence and fibrotic degradation in vivo[J]. Exp Biol Med (Maywood), 2021, 246(4): 447-458. DOI: 10.1177/1535370220960391.
    [27] CIERPKA R, WEISKIRCHEN R, ASIMAKOPOULOS A. Perilipin 5 ameliorates hepatic stellate cell activation via SMAD2/3 and SNAIL signaling pathways and suppresses STAT3 activation[J]. Cells, 2021, 10(9): 2184. DOI: 10.3390/cells10092184.
    [28] MIRANDA JF, SCARINCI LD, RAMOS LF, et al. The modulatory effect of triclosan on the reversion of the activated phenotype of LX-2 hepatic stellate cells[J]. J Biochem Mol Toxicol, 2020, 34(1): e22413. DOI: 10.1002/jbt.22413.
    [29] LI D, LI W, CHEN Y, et al. Anti-fibrotic role and mechanism of Periplaneta americana extracts in CCl4-induced hepatic fibrosis in rats[J]. Acta Biochim Biophys Sin (Shanghai), 2018, 50(5): 491-498. DOI: 10.1093/abbs/gmy024.
    [30] MANKA P, ZELLER A, SYN WK. Fibrosis in chronic liver disease: An update on diagnostic and treatment modalities[J]. Drugs, 2019, 79(9): 903-927. DOI: 10.1007/s40265-019-01126-9.
    [31] TIAN G, KONG D, JIANG T, et al. Complications after percutaneous ultrasound-guided liver biopsy: A systematic review and meta-analysis of a population of more than 12, 000 patients from 51 cohort studies[J]. J Ultrasound Med, 2020, 39(7): 1355-1365. DOI: 10.1002/jum.15229.
    [32] BOYD A, CAIN O, CHAUHAN A, et al. Medical liver biopsy: background, indications, procedure and histopathology[J]. Frontline Gastroenterol, 2020, 11(1): 40-47. DOI: 10.1136/flgastro-2018-101139.
    [33] LEOW WQ, BEDOSSA P, LIU F, et al. An improved qfibrosis algorithm for precise screening and enrollment into non-alcoholic steatohepatitis (NASH) clinical trials[J]. Diagnostics (Basel), 2020, 10(9): 643. DOI: 10.3390/diagnostics10090643.
    [34] DONG M, WU J, YU X, et al. Validation and comparison of seventeen noninvasive models for evaluating liver fibrosis in Chinese hepatitis B patients[J]. Liver Int, 2018, 38(9): 1562-1570. DOI: 10.1111/liv.13688.
    [35] MÁIZ CARRO L, MARTÍNEZ-GARCÍA MA. Use of Hyaluronic Acid (HA) in chronic airway diseases[J]. Cells, 2020, 9(10): 2210. DOI: 10.3390/cells9102210.
    [36] KIM EM, PARK JW, LEE SM, et al. Diagnostic performance of 2-D shear wave elastography on the evaluation of hepatic fibrosis with emphasis on impact of the different region-of-interest methods[J]. Ultrasound Med Biol, 2022, 48(2): 198-208. DOI: 10.1016/j.ultrasmedbio.2021.09.020.
    [37] CUI XW, LI KN, YI AJ, et al. Ultrasound elastography[J]. Endosc Ultrasound, 2022. DOI: 10.4103/EUS-D-21-00151.[OnlineaheadofPrint]
    [38] LEFEBVRE T, WARTELLE-BLADOU C, WONG P, et al. Prospective comparison of transient, point shear wave, and magnetic resonance elastography for staging liver fibrosis[J]. Eur Radiol, 2019, 29(12): 6477-6488. DOI: 10.1007/s00330-019-06331-4.
    [39] WU CY, HSIEH HH, CHU PA, et al. Comparison of 18F-FDG, 18F-Fluoroacetate, and 18F-FEPPA for imaging liver fibrosis in a bile duct-ligated rat model[J]. Mol Imaging, 2021, 2021: 7545284. DOI: 10.1155/2021/7545284.
  • 加载中
计量
  • 文章访问数:  2082
  • HTML全文浏览量:  1547
  • PDF下载量:  283
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-05-15
  • 录用日期:  2022-07-14
  • 出版日期:  2023-01-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回